WilmerHale Represents Fulcrum Therapeutics in Series A Financing from GV

  • 5.10.2017

Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, announced that it has secured additional Series A funding from GV (formerly Google Ventures) to support the continued advancement of its lead programs in Fragile X syndrome and Fascioscapularhumeral muscular dystrophy.
The WilmerHale team representing Fulcrum Therapeutics includes Lia Der Marderosian, Stephanie Singer and Byron Crowe.
Read Fulcrum Therapeutics' press release for more information.